more

Pfizer (PFE)

(Delayed Data from NYSE)

$26.19 USD

-0.05 (-0.19%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $26.24 +0.05 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Research for PFE

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Oncology: Ibrance: Worl...		4,753	5,120	5,437	5,392	4,961
Revenues: FSME-IMMUN/TicoVac [$M]		268	200	185	196	220
Revenues: Pharmaceutical: Oncolog...		433	357	238	137	470
Revenues: Oncology: Xtandi allian...		1,191	1,198	1,185	1,024	838
Revenues: Oncology: Xtandi allian...		1,191	1,198	1,185	1,024	838
Revenues: Specialty Care: Inflect...		490	532	657	659	625
Revenues: Oncology: Bosulif: Worl...		645	575	540	450	365
Pfizer Biopharma: Worldwide [$M]		57,186	98,988	79,557	40,724	--
Revenues: Primary Care: Comirnaty...		11,220	37,806	36,781	--	--
Revenue: Primary Care: Nurtec ODT...	--	928	213	0	--	--
Revenue: Specialty Care: Oxbryta:...		328	73	0	--	--
Revenues: Specialty Care: Zavicef...	--	511	412	413	--	--
Revenues: Pharmaceutical: Primary...		1,777	1,932	1,967	--	--
Revenues: Pharmaceutical: Oncolog...		213	194	187	--	--
Revenues: Pharmaceutical: Oncolog...		539	343	266	--	--
Revenues: Specialty Care: All oth...		2,244	2,350	2,830	--	--
Revenues: Primary Care: Paxlovid:...		1,279	18,933	76	--	--
Revenue: Specialty Care: Cibinqo ...		128	27	--	--	--
Revenue: Business Innovation: Pfi...		44	7	--	--	--
Alliance Revenue [$M]	--	7,582	8,537	7,652	--	--
Revenue: Primary Care: Abrysvo [$...	--	890	--	--	--	--
Product Revenue [$M]	--	50,914	91,793	73,636	--	--
Revenues: Specialty Care: BeneFIX...		424	425	438	454	488
Revenues: Specialty Care: Genotro...		539	360	389	427	498
Revenues: Specialty Care: Zithrom...		406	331	278	276	336
Revenues: Specialty Care: Sulpera...		757	786	683	618	684
Revenues: Oncology: Inlyta: World...		1,036	1,003	1,002	787	477
Revenue: Primary Care: Worldwide ...		30,589	73,023	52,029	--	--
Revenue: Specialty Care: Worldwid...		14,970	13,833	15,194	--	--
Revenues: Oncology: Worldwide [$M...		11,627	12,132	12,333	10,867	9,014
Revenues: Pfizer CentreOne: World...		1,265	1,335	1,731	926	--
Revenues: Primary Care: Eliquis a...		6,747	6,480	5,970	4,949	4,220
Revenues: Primary Care: Prevnar f...		6,440	6,337	5,272	5,850	--
Revenues: Primary Care: Premarin ...		397	455	563	680	734
Revenues: Specialty Care: Vyndaqe...		3,321	2,447	2,015	1,288	473
Revenues: Specialty Care: Xeljanz...		1,703	1,796	2,455	2,437	2,242
Revenues: Specialty Care: Enbrel:...		830	1,003	1,185	1,350	1,699
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Oncology: Ibrance: Unit...		3,151	3,370	3,418	3,634	3,250
Revenues: Oncology: Ibrance: Tota...		1,602	1,751	2,019	1,758	1,710
Revenue: Pharmaceutical: All Othe...		300	216	129	91	219
Revenue: Pharmaceutical: All Othe...		133	140	109	46	251
Revenue: FSME-IMMUN/TicoVac: Tota...		265	198	185	196	--
Revenues: Specialty Care: Inflect...		257	289	385	341	300
Revenues: Specialty Care: Inflect...		233	243	272	318	325
Revenues: Primary Care: Eliquis a...		2,519	2,658	2,810	2,260	1,877
Revenues: Oncology: Bosulif: Unit...		444	375	354	304	243
Revenues: Oncology: Bosulif: Tota...		200	200	186	146	122
Revenue: Pharmaceutical: Oncology...		7,627	7,921	7,736	7,048	5,591
Revenue: Pharmaceutical: Oncology...		4,000	4,210	4,597	3,819	3,422
Pfizer Biopharma: United States [...		26,698	42,083	29,221	21,055	--
Pfizer Biopharma: Total Internati...		30,488	56,905	50,336	19,670	--
Revenues: Specialty Care: Vyndaqe...		1,863	1,245	909	613	191
Revenues: Specialty Care: Vyndaqe...		1,458	1,202	1,106	675	282
Revenue: Specialty Care: Oxbryta:...		323	72	0	--	--
Revenue: Specialty Care: Oxbryta:...		5	0	0	--	--
Revenues: Specialty Care: Zavicef...	--	511	412	107	--	--
Revenues: Pharmaceutical: Primary...		315	340	45	--	--
Revenues: Pharmaceutical: Primary...		1,462	1,592	433	--	--
Revenue: Specialty Care: Cibinqo:...		46	11	--	--	--
Revenue: Specialty Care: Cibinqo:...		81	16	--	--	--
Revenue: Specialty Care: All othe...		1,280	1,351	1,608	--	--
Revenue: Specialty Care: All othe...		965	999	1,223	--	--
Revenue: Pharmaceutical: Specialt...		6,601	5,659	6,156	--	--
Revenue: Pharmaceutical: Specialt...		8,370	8,174	9,038	--	--
Revenue: Pharmaceutical: Oncology...		224	177	141	--	--
Revenue: Pharmaceutical: Oncology...		314	166	125	--	--
Revenue: Pharmaceutical: Oncology...		203	191	187	--	--
Revenue: Pharmaceutical: Oncology...		10	3	--	--	--
Revenue: Primary Care: Abrysvo: U...	--	888	--	--	--	--
Revenue: Primary Care: Abrysvo: T...	--	2	--	--	--	--
Geographic Revenue: United States...		27,088	42,473	29,746	21,455	20,326
Geographic Revenue: Total Interna...		31,408	57,857	51,542	20,196	20,579
Revenue: Primary Care: Comirnaty ...		7,582	8,537	7,652	5,418	4,648
Revenues: Specialty Care: BeneFIX...		200	191	207	215	246
Revenues: Specialty Care: BeneFIX...		225	235	230	239	242
Revenues: Specialty Care: Enbrel:...		830	1,003	1,185	1,350	1,699
Revenues: Specialty Care: Genotro...		386	292	310	299	405
Revenues: Specialty Care: Genotro...		153	68	79	128	93
Revenue: Pharmaceutical: Infectio...		404	328	278	271	338
Revenues: Primary Care: Premarin ...		36	36	38	42	44
Revenues: Primary Care: Premarin ...		361	420	525	637	690
Revenue: Primary Care: Prevnar fa...		2,236	2,305	2,571	2,920	2,638
Revenue: Primary Care: Prevnar fa...		4,204	4,032	2,701	2,930	3,209
Revenue: Specialty Care: Sulperaz...		757	786	683	618	684
Revenues: Oncology: Inlyta: Unite...		642	618	599	523	295
Revenues: Oncology: Inlyta: Total...		394	385	403	264	381
Revenues: Specialty Care: Xeljanz...		1,154	1,129	1,647	1,706	1,636
Revenues: Specialty Care: Xeljanz...		549	668	808	731	606
Revenue: Primary Care: Total Inte...		18,119	44,521	12,410	--	--
Revenue: Primary Care: United Sta...		12,470	28,503	3,815	--	--
Revenue: Primary Care: Nurtec ODT...		20	2	0	--	--
Revenue: Primary Care: Nurtec ODT...		908	211	0	--	--
Revenues: Pfizer CentreOne: Unite...		345	383	524	400	437
Revenues: Pfizer CentreOne: Total...		920	952	1,206	526	374
Revenue: Primary Care: Comirnaty ...		8,816	29,032	10,353	--	--
Revenue: Primary Care: Paxlovid: ...		-1,289	10,514	76	--	--
Revenue: Primary Care: Paxlovid: ...		2,568	8,419	0	--	--
Revenues: Primary Care: Eliquis a...		4,228	3,822	3,160	2,688	2,343

Revenue - Line of Business Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Revenues: Oncology: Ibrance: Worl...		1,087	1,130	1,054	1,118	1,244
Revenues: FSME-IMMUN/TicoVac [$M]		81	100	--	30	91
Revenues: Pharmaceutical: Oncolog...		453	457	397	129	110
Revenues: Oncology: Xtandi allian...		561	495	418	314	313
Revenues: Oncology: Xtandi allian...		561	495	418	314	0
Revenues: Specialty Care: Inflect...		126	97	158	117	121
Revenues: Oncology: Bosulif: Worl...		161	167	145	182	160
Pfizer Biopharma: Worldwide [$M]		--	12,991	14,604	13,867	12,930
Revenues: Primary Care: Comirnaty...		1,422	195	354	5,361	1,307
Revenue: Primary Care: Nurtec ODT...		337	356	178	282	233
Revenue: Specialty Care: Oxbryta:...		17	92	84	96	85
Revenues: Specialty Care: Zavicef...		152	150	125	133	130
Revenues: Pharmaceutical: Primary...		652	651	770	457	452
Revenues: Pharmaceutical: Oncolog...		173	148	116	57	56
Revenues: Pharmaceutical: Oncolog...		206	169	164	146	159
Revenues: Specialty Care: All oth...		218	234	205	558	527
Revenues: Primary Care: Paxlovid:...		2,703	251	2,035	-3,135	202
Revenue: Specialty Care: Cibinqo ...		63	47	42	37	37
Revenue: Business Innovation: Pfi...		25	15	17	20	10
Alliance Revenue [$M]		1,900	2,067	2,172	1,910	1,645
Revenue: Primary Care: Abrysvo [$...		356	56	145	515	--
Revenue: Pharmaceutical: Oncology...		36	32	23	--	--
Revenue: Pharmaceutical- Oncology...		268	279	257	--	--
Revenue: Pharmaceutical- Oncology...		409	394	341	--	--
Revenue: Pharmaceutical- Oncology...		124	121	106	--	--
Revenue: Pharmaceutical- Oncology...		34	33	28	--	--
Oncology: Oncology Biosimilar: Wo...		285	279	264	--	--
Specialty Care: All Other Hospita...		--	1,114	--	--	--
Product Revenue [$M]		15,417	10,871	12,443	12,340	11,587
Royalty Revenue [$M]		384	345	263	--	260
Revenues: Specialty Care: BeneFIX...		88	103	103	103	107
Revenues: Specialty Care: Genotro...		119	119	120	160	158
Revenues: Specialty Care: Zithrom...		83	74	200	152	60
Revenues: Specialty Care: Sulpera...		156	144	167	138	122
Revenues: Oncology: Inlyta: World...		247	252	237	263	252
Revenue: Primary Care: Worldwide ...		9,060	4,952	7,211	6,986	6,287
Revenue: Specialty Care: Worldwid...		4,289	4,083	3,843	3,949	3,757
Revenues: Oncology: Worldwide [$M...		4,043	3,956	3,549	2,932	2,885
Revenues: Pfizer CentreOne: World...		--	278	258	363	291
Revenues: Primary Care: Eliquis a...		1,617	1,877	2,040	1,612	1,498
Revenues: Primary Care: Prevnar f...		1,803	1,359	1,691	1,605	1,854
Revenues: Primary Care: Premarin ...		90	108	--	98	92
Revenues: Specialty Care: Vyndaqe...		1,447	1,323	1,137	961	892
Revenues: Specialty Care: Xeljanz...		321	303	194	493	503
Revenues: Specialty Care: Enbrel:...		169	179	159	203	208
Revenue - Geographic Segments	Qtr Estimate	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023
Revenues: Oncology: Ibrance: Unit...		717	741	679	712	838
Revenues: Oncology: Ibrance: Tota...		371	390	375	405	406
Revenue: Pharmaceutical: All Othe...		238	213	183	93	78
Revenue: Pharmaceutical: All Othe...		214	244	214	36	32
Revenue: FSME-IMMUN/TicoVac: Tota...		--	99	--	30	90
Revenues: Specialty Care: Inflect...		65	43	96	63	61
Revenues: Specialty Care: Inflect...		61	54	62	54	61
Revenues: Primary Care: Eliquis a...		--	615	626	681	615
Revenues: Oncology: Bosulif: Unit...		113	118	101	120	114
Revenues: Oncology: Bosulif: Tota...		48	49	44	62	46
Revenue: Pharmaceutical: Oncology...		3,026	2,918	2,572	1,932	1,881
Revenue: Pharmaceutical: Oncology...		1,017	1,038	977	999	1,004
Pfizer Biopharma: United States [...		--	7,828	9,426	4,490	7,717
Pfizer Biopharma: Total Internati...		--	5,163	5,178	9,376	5,214
Revenues: Specialty Care: Vyndaqe...		960	861	751	534	511
Revenues: Specialty Care: Vyndaqe...		486	462	386	427	381
Revenue: Specialty Care: Oxbryta:...		21	87	80	94	83
Revenue: Specialty Care: Oxbryta:...		-4	5	4	2	2
Revenues: Specialty Care: Zavicef...		152	150	125	133	130
Revenues: Pharmaceutical: Primary...		268	239	315	73	78
Revenues: Pharmaceutical: Primary...		384	411	454	384	374
Revenue: Specialty Care: Cibinqo:...		23	15	23	20	8
Revenue: Specialty Care: Cibinqo:...		40	32	19	18	28
Revenue: Specialty Care: All othe...		85	92	83	298	287
Revenue: Specialty Care: All othe...		133	142	123	260	241
Revenue: Pharmaceutical: Specialt...		2,171	1,973	1,759	1,771	1,746
Revenue: Pharmaceutical: Specialt...		2,118	2,110	2,084	2,178	2,011
Revenue: Pharmaceutical: Oncology...		82	70	59	60	60
Revenue: Pharmaceutical: Oncology...		124	99	104	86	99
Revenue: Pharmaceutical: Oncology...		--	142	111	55	53
Revenue: Pharmaceutical: Oncology...		--	6	5	2	3
Revenue: Primary Care: Abrysvo: U...		318	41	131	513	--
Revenue: Primary Care: Abrysvo: T...		38	15	14	2	--
Revenue: Pharmaceutical: Oncology...		28	25	17	--	--
Revenue: Pharmaceutical: Oncology...		8	7	6	--	--
Oncology: Oncology Biosimilar: Un...		176	177	160	--	--
Oncology: Oncology Biosimilar: To...		109	103	104	--	--
Specialty Care: All Other Hospita...		--	506	--	--	--
Specialty Care: All Other Hospita...		--	608	--	--	--
Geographic Revenue: United States...		12,064	7,892	9,514	4,591	7,804
Geographic Revenue: Total Interna...		5,638	5,391	5,365	9,657	5,427
Revenue: Primary Care: Comirnaty ...		1,900	2,067	2,172	1,064	1,645
Revenues: Specialty Care: BeneFIX...		43	47	47	49	52
Revenues: Specialty Care: BeneFIX...		45	56	56	54	54
Revenues: Specialty Care: Enbrel:...		169	179	159	203	208
Revenues: Specialty Care: Genotro...		92	91	90	112	104
Revenues: Specialty Care: Genotro...		27	28	30	47	54
Revenue: Pharmaceutical: Infectio...		357	74	199	152	59
Revenues: Primary Care: Premarin ...		9	10	--	10	9
Revenues: Primary Care: Premarin ...		80	98	--	88	83
Revenue: Primary Care: Prevnar fa...		495	527	542	612	544
Revenue: Primary Care: Prevnar fa...		1,308	832	1,149	994	1,310
Revenue: Specialty Care: Sulperaz...		156	144	167	138	122
Revenues: Oncology: Inlyta: Unite...		150	151	141	166	153
Revenues: Oncology: Inlyta: Total...		97	101	96	97	98
Revenues: Specialty Care: Xeljanz...		203	181	74	360	371
Revenues: Specialty Care: Xeljanz...		118	122	120	133	132
Revenue: Primary Care: Total Inte...		2,293	2,014	2,117	6,200	2,198
Revenue: Primary Care: United Sta...		6,767	2,938	5,095	787	4,089
Revenue: Primary Care: Nurtec ODT...		23	17	10	7	6
Revenue: Primary Care: Nurtec ODT...		314	339	167	275	227
Revenues: Pfizer CentreOne: Unite...		76	49	71	82	78
Revenues: Pfizer CentreOne: Total...		210	229	187	281	214
Revenue: Primary Care: Comirnaty ...		2,293	137	236	4,297	312
Revenue: Primary Care: Paxlovid: ...		2,313	68	1,800	-3,249	0
Revenue: Primary Care: Paxlovid: ...		389	184	234	114	202
Revenues: Primary Care: Eliquis a...		1,002	1,262	1,413	931	883

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators